BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kips Bay Medical Raises $16.5 Million in IPO


2/11/2011 6:47:27 AM

MINNEAPOLIS, Feb. 10, 2011 /PRNewswire/ -- Kips Bay Medical, Inc. (Nasdaq: KIPS) announced today the pricing of the Company's initial public offering of 2,062,500 shares of its common stock at a price of $8.00 per share. The shares are expected to begin trading on February 11, 2011 on the NASDAQ Global Market under the ticker symbol "KIPS." The closing of the offering is scheduled to take place on February 16, 2011. The Company has granted the underwriters a 45-day option to purchase up to an additional 309,375 shares of common stock at the initial public offering price to cover over-allotments, if any. The Company intends to use the proceeds of the offering to fund the process of seeking regulatory approval to market its external saphenous vein support technology, or eSVS MESH, in the United States, to fund the development and testing of additional applications of its eSVS MESH, to fund certain milestone payments related to acquired intellectual property, and the remainder, if any, for working capital and general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), is acting as sole book-running manager of the offering and Newbridge Securities Corporation, Caris & Company and Chardan Capital Markets, LLC are acting as co-managers. This offering is being made solely by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, New York, NY 10020, via telephone at (212) 430-1710, via email to prospectus@rodm.com or by visiting the U.S. Securities and Exchange Commission website at http://www.sec.gov.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 10, 2011. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kips Bay Medical, Inc:

Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a development stage medical device company focused on developing, manufacturing and commercializing its eSVS MESH for use in coronary artery bypass grafting surgery. Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com.

Contact:


Kips Bay Medical, Inc.

Manny Villafana, Chairman and Chief Executive Officer

Scott Kellen, Chief Financial Officer

Phone: +1-763-235-3540

Email: manny.villafana@kipsbaymedical.com



SOURCE Kips Bay Medical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES